RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06081959, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically and/or cytologically confirmed HR+/HER2- breast cancer based on pathology reports on recent biopsy specimens or other pathological samples;

    Inclusion criterion 2

  3. Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1;

    Exclusion criterion 8

    Prior TROP2 targeted therapy, prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy;

    Exclusion criterion 12

    Patients who received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ;

    Exclusion criterion 13

    Patients with concomitant infections requiring systemic antibiotic therapy within 2 week prior to the first dose of study treatment;

    Exclusion criterion 14

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;

    Inclusion criterion 5

  5. Patients with at least one measurable lesion per RECIST 1.1 criteria; those with only skin or bone lesions cannot be included;

    Inclusion criterion 4

  6. Patients with other malignancies (except cured basal or squamous cell skin cancer or carcinoma in situ of the cervix) within 3 years prior to the first dose;

    Exclusion criterion 2

    Human immunodeficiency virus (HIV) antibody test positive or a history of acquired immunodeficiency syndrome (AIDS), known active syphilis infection;

    Exclusion criterion 10

  7. Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 6 months after the last dose;

    Inclusion criterion 9

    Pregnant or lactating women.

    Exclusion criterion 16

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06081959, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Males or females aged ≥ 18 to ≤ 75 years at the time of signing the ICF;
  • Histologically and/or cytologically confirmed HR+/HER2- breast cancer based on pathology reports on recent biopsy specimens or other pathological samples;
  • Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage;
  • Patients with at least one measurable lesion per RECIST 1.1 criteria; those with only skin or bone lesions cannot be included;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
  • Expected survival ≥ 12 weeks;
  • Adequate organ and bone marrow function;
  • Patients who are eligible for a chemotherapy regimen in the control group;
  • Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 6 months after the last dose;
  • Patients who voluntarily participate in the study and sign the ICF, and able to comply with the visit and related procedures stipulated in the plan.

Exclusion Criteria:

  • Patients with a history of central nervous system (CNS) metastases or current CNS metastases;
  • Patients with other malignancies (except cured basal or squamous cell skin cancer or carcinoma in situ of the cervix) within 3 years prior to the first dose;
  • Patients with any cardio cerebral Vascular disease or cardio cerebral vascular risk factors may affect investigational treatment;
  • Uncontrollable systemic diseases assessed by the investigator;
  • History of (noninfectious) interstitial lung disease (ILD)/noninfectious neumonitis requiring steroid therapy and current ILD/noninfectious pneumonitis, or ILD/noninfectious pneumonitis at screening that cannot be excluded by imaging;
  • Clinically serious lung injuries caused by lung diseases;
  • Patients with active chronic Inflammatory bowel disease, gastrointestinal obstruction, severe ulcer, gastrointestinal perforation, abdominal abscess or acute gastrointestinal bleeding;
  • Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1;
  • Active hepatitis B or hepatitis C;
  • Human immunodeficiency virus (HIV) antibody test positive or a history of acquired immunodeficiency syndrome (AIDS), known active syphilis infection;
  • Known allergy or hypersensitivity to SKB264, or the excipients of SKB264;
  • Prior TROP2 targeted therapy, prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy;
  • Patients who received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ;
  • Patients with concomitant infections requiring systemic antibiotic therapy within 2 week prior to the first dose of study treatment;
  • Patients who have received live vaccines within 30 days prior to the first dose, or are scheduled to receive live vaccines during the study;
  • Pregnant or lactating women.

Quoted from ClinicalTrials.gov, NCT06081959, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06081959, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06081959